Skip to main content
. 2021 Oct 22;28(2):180–187. doi: 10.1002/lt.26312

FIG. 1.

FIG. 1

(A) IgG titers anti‐SARS‐CoV‐2 with median and IQR in pre‐LT candidates at baseline (T0, available for 52 patients), after completion of 2 vaccine doses at T1 (available for all 79 enrolled patients) and at T2 (available for 45 patients); (T0 versus T1, P < 0.001; T1 versus T2, P = 0.33). (B) Individual variations of IgG anti‐SARS‐CoV‐2 from T0 to T1 and T2 after completion of 2 vaccine doses in 36 pre‐LT candidates (T0 versus T1, P < 0.001; T1 versus T2, P = 0.11). Liaison SARS‐CoV‐2 TrimericS IgG assay (DiaSorin, Saluggia, Italy) was used; cutoff value for positivity, 34 BAU/mL.